116 related articles for article (PubMed ID: 36174909)
1. Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Bal C; Avcıoğlu G; Yalçın-Şahiner Ş; Şahiner İV
Environ Toxicol Pharmacol; 2022 Oct; 95():103979. PubMed ID: 36174909
[TBL] [Abstract][Full Text] [Related]
2. OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Danışman M; Bal C
Neurosci Lett; 2024 Jun; 834():137846. PubMed ID: 38821204
[TBL] [Abstract][Full Text] [Related]
3. Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: An improved PCR-RFLP assay for the detection of rs7662029 polymorphism.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Bal C; Yalçın-Şahiner Ş; Avcıoğlu G; Danışman M
Environ Toxicol Pharmacol; 2022 Aug; 94():103902. PubMed ID: 35697190
[TBL] [Abstract][Full Text] [Related]
4. OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Danışman M; Bal C; Oğur B; İspir GZ
Environ Toxicol Pharmacol; 2023 Jun; 100():104143. PubMed ID: 37146669
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
MacKinnon N; Lane D; Scheuermeyer F; Kaczorowski J; Dong K; Orkin AM; Daoust R; Moe J; Andolfatto G; Klaiman M; Yan J; Koh JJ; Crowder K; Atkinson P; Savage D; Stempien J; Besserer F; Wale J; Kestler A
PLoS One; 2024; 19(2):e0297084. PubMed ID: 38315732
[TBL] [Abstract][Full Text] [Related]
6. Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings.
Kosten TR; Morgan C; Kreek MJ
Biol Psychiatry; 1992 Sep; 32(6):523-8. PubMed ID: 1445968
[TBL] [Abstract][Full Text] [Related]
7. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
[TBL] [Abstract][Full Text] [Related]
8. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
[No Abstract] [Full Text] [Related]
9. OPRM1 A118G and serum β-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence.
Gegenhuber B; Weinland C; Kornhuber J; Mühle C; Lenz B
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1418-1428. PubMed ID: 30322771
[TBL] [Abstract][Full Text] [Related]
10. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision.
Elarabi HF; Hasan N; Marsden J; Radwan D; Adem A; Almamari S; Elrasheed A
Pharmacopsychiatry; 2020 Apr; 53(3):115-121. PubMed ID: 32000269
[TBL] [Abstract][Full Text] [Related]
12. Simplified processing and rapid quantification of buprenorphine, norbuprenorphine, and their conjugated metabolites in human plasma using UPLC-MS/MS: Assessment of buprenorphine exposure during opioid use disorder treatment.
Zhao W; Alshogran OY; Zhang H; Joshi A; Krans EE; Caritis S; Shaik IH; Venkataramanan R
J Mass Spectrom; 2024 Apr; 59(4):e5015. PubMed ID: 38501738
[TBL] [Abstract][Full Text] [Related]
13. Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment.
Grist E; Thakkar B; Dacha P; Lutins E; Maxwell M; Martin CE
J Addict Med; 2023 Mar-Apr 01; 17(2):215-218. PubMed ID: 36730907
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.
Greenwald MK; Comer SD; Fiellin DA
Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
17. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
Oller DA; Thornton C; Nuzzo PA; Fanucchi LC
J Addict Med; 2021 May-Jun 01; 15(3):187-190. PubMed ID: 32909986
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
20. Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Yalçın-Şahiner Ş; Ağtaş-Ertan E; Özgür-İlhan İ
Eur J Pharmacol; 2022 Apr; 921():174862. PubMed ID: 35271823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
